GlaxoSmithKline Pharma Q3 net up 27% at Rs 128.67 crore

Standalone total income from operations rose to Rs 746.76 crore for the quarter under consideration

GlaxoSmithKline Pharmaceuticals today reported 27.45% rise in its standalone net profit at Rs 128.67 crore for the third quarter ended September.

The company had posted a net profit of Rs 100.95 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.

Standalone total income from operations also rose to Rs 746.76 crore for the quarter under consideration from Rs 626.65 crore for the same period year-ago, it added.

The company follows January-December financial year.

Established in 1924 in India, GlaxoSmithKline Pharmaceuticals' product portfolio includes prescription medicines and vaccines.

The company's prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.